13 Best Long Term Low Risk Stocks to Buy Now

9. Boston Scientific Corporation (NYSE:BSX)

Beta (5Y Monthly): 0.69

5-Year Return: 100.4%

On February 5, Truist lowered its price objective on Boston Scientific Corporation (NYSE:BSX) to $95 from $120. The firm maintained a Buy rating on the stock. In a note to clients, the analyst said the sharp pullback after earnings appeared excessive, especially with the stock now trading at a discount to faster-growing peers.

The reaction followed the company’s February 4 earnings release, which highlighted weaker-than-expected results in the electrophysiology business. That unit, which focuses on minimally invasive treatments for heart rhythm disorders, is a key part of Boston Scientific’s growth narrative. Fourth-quarter sales in the segment reached $890 million, falling short of the $933 million analysts had been expecting, according to RBC Capital Markets. The miss unsettled investors, who questioned whether growth in the segment was losing momentum. Citi analyst Joanne Wuensch said those worries were justified.

Sales of the Watchman device, used to help prevent strokes in patients with atrial fibrillation, also came in about 1% below forecasts. Analysts attributed the shortfall mainly to softer demand in the US market. For the year ahead, Boston Scientific forecasts adjusted earnings per share of $3.43 to $3.49. The midpoint of that range landed just under Wall Street expectations of $3.47, based on data from LSEG. On the quarter, revenue totaled $5.29 billion and adjusted earnings were 80¢ per share, both roughly in line with estimates.

Looking further out, the company expects organic revenue growth of 10% to 11% in 2026, pointing to a slower pace compared with the 15.8% organic growth reported in 2025.

Boston Scientific Corporation (NYSE:BSX) develops and sells medical devices used across a wide range of interventional procedures around the world.